As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...